Healthcare Facilities company Rainbow Children's Medicare announced Q4FY23 & FY23 results: Q4FY23 vs Q4FY22: Revenue: Rs 3,169.66 million vs Rs 2,124.47 million, up 49.20% YoY EBITDA: Rs 980.07 million vs Rs 481.33 million, up 103.62% YoY EBITDA %: 30.92% vs 22.66%, up 826 bps YoY PAT: Rs 538.63 million vs Rs 122.60 million, up 339.34% YoY PAT %: 16.99% vs 5.77%, up 1,122 bps YoY FY23 vs FY22: Revenue: Rs 11,735.74 million vs Rs 9,737.58 million, up 20.52% YoY EBITDA: Rs 3,963.77 million vs Rs 3,048.75 million, up 30.01% YoY EBITDA %: 33.78% vs 31.31%, up 247 bps YoY PAT: Rs 2,123.77 million vs Rs 1,386.73 million, up 53.15% YoY PAT %: 18.10% vs 14.24%, up 386 bps YoY Commenting on the performance for Q4FY23, Dr. Ramesh Kancharla, Chairman & Managing Director, Rainbow Children’s Medicare (RCML), said, “I am pleased to inform you that the company has delivered robust quarterly performance, led by high patient footfall across hospitals. The revenues for Q4FY23 were Rs 3,169.66 million, which is a growth of 49.20% compared to Rs 2,124.47 million in Q4FY22. The EBIDTA for Q4FY23 was Rs 980.07 million, which is a growth of 103.62% compared to Rs 481.33 million in Q4FY22, and the PAT for Q4FY23 was Rs 538.63 million, which is a growth of 339.34% compared to Rs 122.60 million in Q4FY22. The company is focused on executing the business plan, put forth during the IPO, of adding 1000 beds across the target markets. The proposed expansion for the current financial year includes the addition of ~270 beds in Central Hyderabad (60 beds), Hydernagar (50 beds), Anna Nagar (80 beds), and Sarjapur (80 beds). Additional ~160 beds are slated for commencement in the next financial year at Rajahmundry (100 beds) and a new spoke hospital in Bengaluru (60 beds). Furthermore, the company aims to increase its bed count by ~400 across the National Capital Region by FY26-27. The company remains committed to fulfilling its mission of delivering excellent multi-disciplinary pediatric and perinatal care and strives to enhance its service offerings by making constant improvements.” Result PDF
Conference Call with Rainbow Childrens Medicare Management and Analysts on Q3FY23 Performance and Outlook. Listen to the full earnings transcript.
Rainbow Children Medicare announced Q3FY23 results: Q3FY23: Revenues for Q3FY23 stood at Rs 3,064.04 million, growth of 23.17% compared to Rs 2,487.56 million in Q3FY22. EBIDTA for Q3FY23 was Rs 1,067.56 million, growth of 19.59% compared to Rs 892.68 million in Q3FY22 PAT for Q3 FY23 was Rs 582.44 million, growth of 28.87% compared to Rs 451.95 million in Q3FY22. Commenting on the performance for Q3FY23, Ramesh Kancharla, Chairman & Managing Director, Rainbow Children’s Medicare Limited (RCML), said, “I am pleased to inform you that the company has delivered robust quarterly performance, led by high patient footfalls across hospitals in every geography. We are pleased to share that the projects which are under execution are progressing well and will commence operations within the targeted timelines.” Result PDF
Rainbow Childrens Medicare announced Q1FY23 results: The revenues for Q1FY23 stood at Rs.2371.52 million, when compared to Rs. 2,463.57 million in Q1FY22 The operating EBIDTA for Q1FY23 was Rs. 820.91 million, which is a growth of 5% compared to Rs. 782.64 million in Q1FY22 PAT for Q1FY23 was Rs. 387.61 million, which is a growth of 8% compared to Rs. 358.80 million in Q1FY22. Commenting on the performance for Q1 FY2023 Dr. Ramesh Kancharla, Chairman & Managing Director, Rainbow Children’s Medicare Limited (RCML) said, “We have witnessed business normalising to pre-COVID levels with all the operating parameters demonstrating healthy growth compared to previous quarters, with schools having reopened across the country and children returning to near normal life. We expect healthy growth across our pediatric super specialty services as we are witnessing strong demand for these services across the hospitals. The OMR, Chennai spoke hospital is expected to commence operations in the current quarter and all other projects under execution are progressing well and are expected to commence operations within the stated timelines. The revenues for Q1FY23 stood at Rs. 2371.52 million, when compared to Rs. 2,463.57 million in Q1FY22. However, adjusting for the COVID vaccine revenue of 440 mn in Q1FY22, the revenue for Q1FY23 has grown at 17% compared to the revenue in Q1FY22. The operating EBIDTA for Q1FY23 was Rs. 820.91 million, which is a growth of 5% compared to Rs. 782.64 million in Q1FY22 and the PAT for Q1FY23 was Rs. 387.61 million, which is a growth of 8% compared to Rs. 358.80 million in Q1FY22. With focus on pediatric super-specialties and quaternary care, we are building a powerful ecosystem backed by neonatal and pediatric intensive care services. As our network of hospitals expands we shall be in a better position to serve a larger patient pool, addressing the strong underlying requirement for children focused quality hospitals in the country.” Result PDF